Dociparstat in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia

PHASE3TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

April 30, 2021

Primary Completion Date

May 16, 2022

Study Completion Date

May 16, 2022

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

Dociparstat

Dociparstat is a glycosaminoglycan derived from porcine heparin.

OTHER

Control

0.9% Normal Saline

Trial Locations (14)

10029

Mount Sanai School of Medicine, New York

10595

New York Medical College, Hawthorne

22903

University of Virginia Cancer Center, Charlottesville

27834

East Carolina University Vidant Medical Center, Greenville

29303

Spartanburg Medical Gibbs Cancer Center, Spartanburg

40207

Norton Cancer Institute, St. Matthews Campus, Louisville

44718

Gabrail Cancer Center, Canton

48202

Henry Ford Health System, Detroit

55407

Allina Health System / Virginia Piper Cancer Institute, Minneapolis

66205

University of Kansas Cancer Center, Westwood

70112

Tulane University School of Medicine, New Orleans

75246

Baylor, Dallas

84112

University of Utah / Huntsman Cancer Institute, Salt Lake City

92868

UC Irvine Medical Center, Orange

Sponsors
All Listed Sponsors
lead

Jazz Pharmaceuticals

INDUSTRY